Shares of Mast Therapeutics Inc. (MSTX) were down over 83% in extended trading on Tuesday after the company announced that its phase III study of Vepoloxamer in sickle cell disease did not meet the primary efficacy endpoint.
from RTT - Biotech http://ift.tt/2d7xt7C
via IFTTT
No comments:
Post a Comment